umbralisib
Selected indexed studies
- Umbralisib: First Approval. (Drugs, 2021) [PMID:33797740]
- Umbralisib. (, 2012) [PMID:37956236]
- Umbralisib Tosylate. (Am J Health Syst Pharm, 2021) [PMID:33880512]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Umbralisib: First Approval. (2021) pubmed
- Umbralisib. (2012) pubmed
- Umbralisib Tosylate. (2021) pubmed
- The evidence to date on umbralisib for the treatment of refractory marginal zone lymphoma and follicular lymphoma. (2022) pubmed
- FDA Evaluating Possible Serious Risks From Umbralisib. (2022) pubmed
- Umbralisib: Walking the Tightrope of PI3K Inhibition in Indolent NHL. (2021) pubmed
- A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib. (2022) pubmed
- Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. (2021) pubmed
- Umbralisib: Treatment for a Rare Lymphoma? (2019) pubmed
- Umbralisib-Induced Immune-Mediated Colitis: A Concerning Adverse Effect of the Novel PI3Kδ/CK1ε Inhibitor. (2021) pubmed